CHRS - Coherus BioSciences, Inc.
13.05 0.00 (0.00%)
After hours: 4:59PM EDT
| Previous Close | 13.33 |
| Open | 13.20 |
| Bid | 11.69 x 2200 |
| Ask | 24.85 x 4000 |
| Day's Range | 12.97 - 13.20 |
| 52 Week Range | 8.05 - 20.66 |
| Volume | 446,537 |
| Avg. Volume | 574,403 |
| Market Cap | 885.061M |
| Beta (3Y Monthly) | 4.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.83 |
- Motley Fool•4 days ago
Here's Why Coherus BioSciences Fell 18.1% in September
Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.
- GlobeNewswire•7 days ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Oct. 09, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective October 8, 2018, the compensation committee of the company’s.
Market Realist•14 days agoMylan’s Biosimilar of Neulasta Expected to Be a Key Growth Driver
Why Are Wall Street Analysts Bullish on Mylan Stock? Mylan’s (MYL) Fulphila (pegfilgrastim), a biosimilar of Amgen’s (AMGN) Neulasta, received a positive CHMP (Committee for Medicinal Products for Human Use) opinion on September 21. Two other Neulasta biosimilars—Cinfa Biotech’s Pelmeg and Sandoz’s Ziextenzo—also received a positive CHMP opinion on September 21.
GuruFocus.com•19 days agoAmgen's Neulasta Has a New Competitor in Europe
Amgen Inc. (AMGN) has not been affected by the decision of the European Commission to approve Coherus BioSciences' (CHRS) UDENYCA for commercialization in Europe. UDENYCA, one of the first pegfilgrastim products to gain the European marketing authorization, is a biosimilar of Amgen's Neulasta. Warning! GuruFocus has detected 1 Warning Sign with FB.
- GlobeNewswire•20 days ago
Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)
Coherus BioSciences, Inc. (CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar. UDENYCA™ is one of the first pegfilgrastim biosimilars to gain marketing authorization in Europe. "Today’s EC approval decision is the first marketing authorization for Coherus, an important step forward in realizing our mission of increasing access to biologic treatments to patients globally,” said Denny Lanfear, President and CEO of Coherus BioSciences.
Markit•21 days agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding CHRS is favorable, with net inflows of $5.07 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
- GlobeNewswire•25 days ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Sept. 21, 2018-- Coherus BioSciences, Inc., today announced that effective September 20, 2018, the compensation committee of the company’ s board of directors granted 6 new employees ...
- GlobeNewswire•29 days ago
Coherus BioSciences Management to Present at the 2018 Cantor Global Healthcare Conference in October
REDWOOD CITY, Calif., Sept. 17, 2018-- Coherus BioSciences, Inc., today announced that senior management will be presenting at the 2018 Cantor Global Healthcare Conference being held in New York on Tuesday, ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of CHRS earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 Coherus BioSciences Inc Earnings Call
- GlobeNewswire•2 months ago
Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Markit•2 months agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GlobeNewswire•2 months ago
Coherus BioSciences Management to Participate in Two Investor Healthcare Conferences in September
REDWOOD CITY, Calif., Aug. 20, 2018-- Coherus BioSciences, Inc., today announced that senior management will participate in two upcoming investor healthcare conferences in September.. Management participation ...
- GlobeNewswire•2 months ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 17, 2018-- Coherus BioSciences, Inc., today announced that effective August 14, 2018, the company’ s board of directors granted 3 new employees options to purchase an aggregate ...
- Associated Press•2 months ago
Coherus BioSciences: 2Q Earnings Snapshot
The Redwood City, California-based company said it had a loss of 68 cents per share. Coherus BioSciences shares have more than doubled since the beginning of the year. In the final minutes of trading on ...
- GlobeNewswire•2 months ago
Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results
REDWOOD CITY, Calif., Aug. 08, 2018-- Coherus BioSciences, Inc., today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018.. Second Quarter 2018 Corporate Highlights ...
- ACCESSWIRE•2 months ago
Coherus BioSciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Coherus BioSciences, Inc. (NASDAQ: CHRS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern ...
- GlobeNewswire•3 months ago
Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA™ (Pegfilgrastim Biosimilar Candidate)
Coherus BioSciences, Inc. (CHRS), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®1) biosimilar candidate. UDENYCA has the opportunity to become one of the first pegfilgrastim biosimilars to gain Marketing Authorization in Europe.
- GlobeNewswire•3 months ago
Market Trends Toward New Normal in United Technologies, Paychex, Coherus BioSciences, InfraREIT, Cousins Properties, and Engility — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United ...
- GlobeNewswire•3 months ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., July 25, 2018-- Coherus BioSciences, Inc., today announced that effective July 19, 2018, the compensation committee of the company’ s board of directors granted 11 new employees options ...
- GlobeNewswire•3 months ago
Coherus BioSciences to Report Second Quarter 2018 Financial Results on August 8th
REDWOOD CITY, Calif., July 24, 2018-- Coherus BioSciences, Inc., today announced that its second quarter 2018 financial results will be released after market close on Wednesday, August 8, 2018. Starting ...
- Motley Fool•3 months ago
Here's Why Coherus Biosciences Rose Over 21% Today
The biosimilar developer received some good news from a regulator.
Markit•3 months agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding CHRS totaled $561 million.
- ACCESSWIRE•3 months ago
Free Technical Research on Clovis Oncology and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on CLVS sign up now at www.wallstequities.com/registration. On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories.
- Zacks•4 months ago
Implied Volatility Surging for Coherus BioSciences (CHRS) Stock Options
Investors in Coherus BioSciences (CHRS) need to pay close attention to the stock based on moves in the options market lately.
